What’s New in MASH: Strengthening Your Diagnostic and Management Muscles

Target Audience

The educational design of this activity addresses the needs of gastroenterologists, hepatologists, specialist nurse practitioners (NPs), and physician associates (PAs) involved in the treatment of patients with metabolic dysfunction–associated steatohepatitis (MASH).

Program Overview

Recently, terminology and diagnostic criteria around MASH, which is a growing concern for clinicians, has been updated to more accurately reflect the close relationship between liver disease and cardiometabolic risk factors. Diagnosis and fibrosis staging have become easier and more accessible over the last several years with the rise of noninvasive tests (NITs), largely removing the need for liver biopsy. To date, there is 1 pharmacotherapy approved by the US Food and Drug Administration, though other therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may be useful in addressing obesity and cardiovascular disease, which are closely linked to MASH. It is critical that clinicians be up to date on diagnostic strategies, nonpharmacologic and pharmacologic treatment strategies, and required disease monitoring. Drs. Naim Alkhouri and Sonal Kumar describe recent advances in MASH diagnosis and management through an interactive platform.

Educational Objectives

After completing this activity, the participant should be better able to:

• Recognize the chronic nature and pathophysiology of MASH, including its relationship to cardiometabolic diseases
• Incorporate the most appropriate noninvasive tools to diagnose, stage, and monitor MASH
• Discuss the role of GLP-1 RAs and other emerging therapies for the treatment of MASH and its cardiometabolic comorbidities
• Create comprehensive treatment plans for patients with MASH, including considerations for cardiometabolic comorbidities

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Integritas Communications and Global Education Group (Global) adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

Naim Alkhouri, MD, FAASLD: Consulting Fees: 89Bio, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus; Fees for Non-CE Services: AbbVie, Alexion, Echosens, Gilead, Intercept, Ipsen, Madrigal, Perspectum; Contracted Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus

Sonal Kumar, MD, MPH: Consulting Fees: CymaBay Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Ipsen; Fees for Non-CE Services: CymaBay Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Ipsen; Contracted Research: CymaBay Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Ipsen, Galectin Therapeutics, Gilead Sciences

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.